生物医药Ⅱ行业周报：双特异性银屑病关节炎疗法2b／3期试验达主要终点

Investment Rating - The industry rating is "Positive," with expectations of overall returns exceeding the CSI 300 Index by more than 5% in the next six months [2]. Core Insights - The report highlights that the biopharmaceutical sector has shown a performance increase of 1.78% as of March 12, 2024, outperforming the CSI 300 Index by 1.55 percentage points, ranking 7th among 31 sub-industries in the Shenwan classification [1]. - Notable sub-industry performances include vaccines (+4.00%), medical research outsourcing (+3.38%), and hospitals (+2.36%), while pharmaceutical distribution (+0.42%), in vitro diagnostics (+0.48%), and medical devices (+0.79%) lagged behind [1]. - The report mentions that ACELYRIN's candidate drug Izokibep for treating psoriatic arthritis has reached its primary endpoint in a global Phase 2b/3 clinical trial, showing significant symptom relief in patients [1]. Summary by Sections Industry Overview - The biopharmaceutical sector is currently rated as "Positive," indicating a favorable outlook for investment [2]. Company News - ACELYRIN announced that its IL-17A inhibitor, Izokibep, has achieved significant results in clinical trials for psoriatic arthritis, marking a potential breakthrough in treatment options [1]. - Other companies mentioned include Fosun Pharma, which received approval for clinical trials of HLX6018 for idiopathic pulmonary fibrosis, and China National Pharmaceutical Group, which has received approval for additional specifications of tranexamic acid injection [1].